Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATILDA: Durvalumab + Tremelimumab in High Mutational Load Solid Tumors
NCT03982173Phase 2Withdrawn
- Sponsor
- Gustave Roussy
- Start
- Sep 2020
- Primary completion
- Sep 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in colorectal cancer (CRC), triple-negative breast cancer (TNBC), prostate adenocarcinoma and 2 more, sponsored by Gustave Roussy. Primary endpoint: Objective tumour response rate at 12 weeks. Planned start Sep 2020; status: withdrawn.
02
Drugs
durvalumabtremelimumab
03
Conditions
colorectal cancer (CRC)triple-negative breast cancer (TNBC)prostate adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT03982173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982173.